Country: কানাডা
ভাষা: ইংরেজি
সূত্র: Health Canada
CEFTRIAXONE (CEFTRIAXONE SODIUM)
FRESENIUS KABI CANADA LTD
J01DD04
CEFTRIAXONE
100G
POWDER FOR SOLUTION
CEFTRIAXONE (CEFTRIAXONE SODIUM) 100G
INTRAVENOUS
100G
Prescription
THIRD GENERATION CEPHALOSPORINS
Active ingredient group (AIG) number: 0117292009; AHFS:
APPROVED
2015-03-06
_Ceftriaxone for Injection – Product Monograph _ _ _ _ Page 1 of 59 _ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR CEFTRIAXONE FOR INJECTION Sterile Powder for Solution, 500 mg, 1 g, 2 g ceftriaxone (as ceftriaxone sodium) per vial Pharmacy Bulk Package 10 g ceftriaxone (as ceftriaxone sodium) per vial 100 g ceftriaxone (as ceftriaxone sodium) in SmartPak® Pharmacy Bulk Package Intravenous or Intramuscular USP Antibiotic Fresenius Kabi Canada Ltd. 165 Galaxy Blvd. Suite 100 Toronto, ON M9W 0C8 Date of Initial Authorization: DEC 15, 2006 Date of Revision: MAY 15, 2023 Submission Control No.: 272154 _Ceftriaxone for Injection – Product Monograph _ _ _ _ Page 2 of 59 _ RECENT MAJOR LABEL CHANGES 7 WARNINGS AND PRECAUTIONS, General, Severe Cutaneous Adverse Reactions 01/2022 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGES ........................................................................................... 2 TABLE OF CONTENTS ............................................................................................................. 2 PART I: HEALTH PROFESSIONAL INFORMATION ..................................................................... 4 1 INDICATIONS .............................................................................................................. 4 1.1 Pediatrics ................................................................................................................... 4 1.2 Geriatrics ................................................................................................................... 5 2 CONTRAINDICATIONS ................................................................................................. 5 4 DOSAGE AND ADMINISTRATION ................................................................................. 5 4.1 Dosing Considerations ............................................................................................... 5 4.2 Recommended Dose সম্পূর্ণ নথি পড়ুন